| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802968701023 | 296870102 | TOLDESOR PR.CAP 2MG/CAP BTx28 (σε PVC/PE/PVDC-ALU blisters) (σε PVC/PE/PVDC-ALU blisters) | 5.40 | 5.66 | 7.80 |
| 05/2018 | 2802968702037 | 296870203 | TOLDESOR PR.CAP 4MG/CAP BTx28 (σε PVC/PE/PVDC-ALU blisters) (σε PVC/PE/PVDC-ALU blisters) | 7.36 | 7.72 | 10.64 |
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, act as competitive antagonists at muscarinic receptors. This antagonism results in inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.
1.9-3.7 hours
Following administration of a 5-mg oral dose of 14C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days.
* 113 ± 26.7 L